Advancing Biomarker Qualification: FDA Perspective on Efficiency, Surrogate Endpoints, and Future Directions

Therapeutic Innovation & Regulatory Science 2026

View at publisher

Authors: Vanitha J. Sekar, Jeffrey N. Siegel

DOI: 10.1007/s43441-025-00911-x

Cited by: 1

References: 3

Fields of Study & Subjects

Statistical Methods in Clinical Trials Health Systems Economic Evaluations Quality of Life Biosimilars and Bioanalytical Methods

References 3